Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats-Reference-Cited by-同舟云学术

Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats

Published:2006 Issue:7 Volume:59 Page:435-444
ISSN:0887-4476
Container-title:Synapse
language:en
Short-container-title:Synapse

Author:

Bové J.,Serrats J.,Mengod G.,Cortés R.,Aguilar E.,Marin C.

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience

Reference65 articles.

1. Striatal fosB Expression Is Causally Linked with l-DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease

2. Time course of striatal ΔFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment

3. Agonist-Induced Phosphorylation of the κ-Opioid Receptor

4. Adenosine A2Aantagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats

5. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittentL-dopa and A2A receptor blockade plusL-Dopa in dopamine-denervated rats

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia;Journal of Neural Transmission;2018-02-02

2. Adenosine A2A Receptor Antagonists as Drugs for Symptomatic Control of Parkinson’s Disease in Preclinical Studies;Current Topics in Neurotoxicity;2015

3. A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists;Neurotoxicity Research;2013-12-10

4. Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease;Adenosine;2012-07-23

5. Neurotoxin-based models of Parkinson's disease;Neuroscience;2012-06